{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T00:24:40.783329+00:00","company":{"ticker":"LONA","cik":1620463,"company_name":"LeonaBio, Inc."},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"d882745ca1ba481e9fca8dacc1d5932461433beb","cik":1620463,"ticker":"LONA","company_name":"LeonaBio, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":null},"claim":"LeonaBio, Inc. reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"On May 7, 2026, LeonaBio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-211867","anchor_url":"https://secwatch.observer/filing/0001193125-26-211867#claim-d882745ca1ba481e9fca8dacc1d5932461433beb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1620463/000119312526211867/0001193125-26-211867-index.htm"},{"fact_type":"earnings_release","fact_key":"cafbd0202d773a5987af415c0ca93f934e79237b","cik":1620463,"ticker":"LONA","company_name":"LeonaBio, Inc.","filed_at":"2026-03-26T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the year ended December 31, 2025","report_date":"2025-03-26","result_type":"reported_results","revenue_text":null},"claim":"LeonaBio, Inc. reported financial results for the year ended December 31, 2025.","evidence_excerpt":"On March 26, 2025, LeonaBio, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-126579","anchor_url":"https://secwatch.observer/filing/0001193125-26-126579#claim-cafbd0202d773a5987af415c0ca93f934e79237b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1620463/000119312526126579/0001193125-26-126579-index.htm"},{"fact_type":"governance_change","fact_key":"69eae61f6a6e9483c12cc498b59fe6d70dee29ad","cik":1620463,"ticker":"LONA","company_name":"LeonaBio, Inc.","filed_at":"2026-01-09T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-01-09","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws to reflect the name change to LeonaBio, Inc."},"claim":"LeonaBio, Inc.: Amended and restated bylaws to reflect the name change to LeonaBio, Inc (effective 2026-01-09).","evidence_excerpt":"Additionally, effective January 9, 2026, the Board approved an amendment and restatement of the Company’s bylaws (the “Amended and Restated Bylaws”) to reflect the Name Change.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-008904","anchor_url":"https://secwatch.observer/filing/0001193125-26-008904#claim-69eae61f6a6e9483c12cc498b59fe6d70dee29ad","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1620463/000119312526008904/0001193125-26-008904-index.htm"},{"fact_type":"governance_change","fact_key":"312235b1bf84c3e1e05e8ef2a22d0f7858c6b515","cik":1620463,"ticker":"LONA","company_name":"LeonaBio, Inc.","filed_at":"2026-01-09T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-01-09","item_codes_triggered":["5.03"],"summary_text":"Certificate of Amendment to Amended and Restated Certificate of Incorporation to change corporate name from Athira Pharma, Inc. to LeonaBio, Inc."},"claim":"LeonaBio, Inc.: Certificate of Amendment to Amended and Restated Certificate of Incorporation to change corporate name from Athira Pharma, Inc. to LeonaBio, Inc (effective 2026-01-09).","evidence_excerpt":"Effective January 9, 2026, Athira Pharma, Inc. (the “Company”) changed its name to LeonaBio, Inc. (the “Name Change”). The Name Change was approved by the Company’s Board of Directors (the “Board”) and was effectuated through the filing of a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-008904","anchor_url":"https://secwatch.observer/filing/0001193125-26-008904#claim-312235b1bf84c3e1e05e8ef2a22d0f7858c6b515","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1620463/000119312526008904/0001193125-26-008904-index.htm"},{"fact_type":"governance_change","fact_key":"9b262e9deccc65e8e31697ba040ef658e086e376","cik":1620463,"ticker":"LONA","company_name":"LeonaBio, Inc.","filed_at":"2025-09-11T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-09-17","item_codes_triggered":["5.03"],"summary_text":"Amended certificate of incorporation to effect a 10-for-1 reverse stock split"},"claim":"LeonaBio, Inc.: Amended certificate of incorporation to effect a 10-for-1 reverse stock split (effective 2025-09-17).","evidence_excerpt":"On September 10, 2025, the Company filed a certificate of amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware to effect a 10-for-1 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share, effective as of 5:00 p.m., Eastern Time, on September 17, 2025 (the “Reverse Stock Split”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-114093","anchor_url":"https://secwatch.observer/filing/0000950170-25-114093#claim-9b262e9deccc65e8e31697ba040ef658e086e376","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1620463/000095017025114093/0000950170-25-114093-index.htm"},{"fact_type":"earnings_release","fact_key":"c662bb4652b64d74c7a424d12987e053f1ff717c","cik":1620463,"ticker":"LONA","company_name":"LeonaBio, Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-05-15","result_type":"reported_results","revenue_text":null},"claim":"LeonaBio, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 15, 2024, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2024.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0000950170-24-060452","anchor_url":"https://secwatch.observer/filing/0000950170-24-060452#claim-c662bb4652b64d74c7a424d12987e053f1ff717c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1620463/000095017024060452/0000950170-24-060452-index.htm"}]}